VivoSeq
Oncology

Gastric Cancer Peritoneal Metastases

2

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Gastric Cancer Peritoneal Metastases is an early-stage landscape with 2 programs across 0 companies. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Intraperitoneal Paclitaxel

ECOG-ACRIN Cancer Research Group

Standard Systemic Therapy

Magnus Nilsson

Approved
No programs

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastases - IPa-Gastric
Recruiting·—·Phase 3·NCT07304271·262 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)